<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=129980757405201&amp;ev=PageView&amp;noscript=1">
The Role of New Drugs

for Systolic Heart Failure



Fill out the form to watch the webinar now

This TRC Hot Topic webinar features an expert panel discussion on the pros and cons of Entresto (sacubitril/valsartan) or Corlanor (ivabradine) for the treatment of systolic heart failure, or heart failure with reduced ejection fraction. Listen as heart failure experts give guidance on pressing questions:

  • What is "standard treatment" of heart failure with reduced ejection fraction?
  • When should Entresto be considered instead of an ACEI or ARB?
  • What are the risks associated with starting Entresto?
  • How should patients be switched from an ACEI or ARB to Entresto?
  • What is the role of Corlanor  in heart failure with reduced ejection fraction?